Hussein Yassine, MD, Keck School of Medicine, University of Southern California, Los Angeles, CA, describes how lipidomics, and a better understanding of the brain’s cellular lipidomic response to Alzheimer’s disease (AD), could guide the development of future disease-modifying agents. Lipids and lipid intermediates are intrinsic to brain function. Some of the lipids that are enriched in the brain include omega-3s, omega-6s, polyunsaturated fatty acids, and lipid mediators of neuroinflammation and synaptic biology. Dr Yassine suggests that developing tools to measure the lipidome and better understand the changes in lipid composition during the disease course of AD, could provide novel insights into AD pathology and treatment. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
